S&P 500   3,841.42 (-1.52%)
DOW   30,857.74 (-1.27%)
QQQ   281.69 (-2.72%)
AAPL   134.05 (-2.40%)
MSFT   247.68 (-2.16%)
FB   190.19 (-0.58%)
GOOGL   2,127.00 (-3.65%)
AMZN   2,109.15 (-1.73%)
TSLA   645.63 (-8.99%)
NVDA   160.42 (-6.32%)
BABA   85.37 (-2.65%)
NIO   15.90 (-4.56%)
AMD   89.59 (-7.32%)
CGC   5.37 (-8.52%)
MU   66.62 (-4.01%)
T   20.23 (+0.10%)
GE   74.08 (-2.19%)
F   12.28 (-4.44%)
DIS   100.71 (-2.36%)
AMC   11.57 (-11.54%)
PFE   51.82 (+2.31%)
PYPL   78.16 (-3.84%)
NFLX   181.37 (-1.15%)
S&P 500   3,841.42 (-1.52%)
DOW   30,857.74 (-1.27%)
QQQ   281.69 (-2.72%)
AAPL   134.05 (-2.40%)
MSFT   247.68 (-2.16%)
FB   190.19 (-0.58%)
GOOGL   2,127.00 (-3.65%)
AMZN   2,109.15 (-1.73%)
TSLA   645.63 (-8.99%)
NVDA   160.42 (-6.32%)
BABA   85.37 (-2.65%)
NIO   15.90 (-4.56%)
AMD   89.59 (-7.32%)
CGC   5.37 (-8.52%)
MU   66.62 (-4.01%)
T   20.23 (+0.10%)
GE   74.08 (-2.19%)
F   12.28 (-4.44%)
DIS   100.71 (-2.36%)
AMC   11.57 (-11.54%)
PFE   51.82 (+2.31%)
PYPL   78.16 (-3.84%)
NFLX   181.37 (-1.15%)
S&P 500   3,841.42 (-1.52%)
DOW   30,857.74 (-1.27%)
QQQ   281.69 (-2.72%)
AAPL   134.05 (-2.40%)
MSFT   247.68 (-2.16%)
FB   190.19 (-0.58%)
GOOGL   2,127.00 (-3.65%)
AMZN   2,109.15 (-1.73%)
TSLA   645.63 (-8.99%)
NVDA   160.42 (-6.32%)
BABA   85.37 (-2.65%)
NIO   15.90 (-4.56%)
AMD   89.59 (-7.32%)
CGC   5.37 (-8.52%)
MU   66.62 (-4.01%)
T   20.23 (+0.10%)
GE   74.08 (-2.19%)
F   12.28 (-4.44%)
DIS   100.71 (-2.36%)
AMC   11.57 (-11.54%)
PFE   51.82 (+2.31%)
PYPL   78.16 (-3.84%)
NFLX   181.37 (-1.15%)
S&P 500   3,841.42 (-1.52%)
DOW   30,857.74 (-1.27%)
QQQ   281.69 (-2.72%)
AAPL   134.05 (-2.40%)
MSFT   247.68 (-2.16%)
FB   190.19 (-0.58%)
GOOGL   2,127.00 (-3.65%)
AMZN   2,109.15 (-1.73%)
TSLA   645.63 (-8.99%)
NVDA   160.42 (-6.32%)
BABA   85.37 (-2.65%)
NIO   15.90 (-4.56%)
AMD   89.59 (-7.32%)
CGC   5.37 (-8.52%)
MU   66.62 (-4.01%)
T   20.23 (+0.10%)
GE   74.08 (-2.19%)
F   12.28 (-4.44%)
DIS   100.71 (-2.36%)
AMC   11.57 (-11.54%)
PFE   51.82 (+2.31%)
PYPL   78.16 (-3.84%)
NFLX   181.37 (-1.15%)
NASDAQ:BDSI

BioDelivery Sciences International (BDSI) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$5.59
▼
$5.60
50-Day Range
$5.54
▼
$5.60
52-Week Range
$2.50
▼
$5.62
Volume
2.09 million shs
Average Volume
3.34 million shs
Market Capitalization
$577.05 million
P/E Ratio
6.74
Dividend Yield
N/A
Beta
0.56

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter.

BioDelivery Sciences International logo

About BioDelivery Sciences International

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Headlines

May 10, 2022 | seekingalpha.com
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call Transcript
May 2, 2022 | thestreet.com
Jim Cramer's Top Stock Picks: DF MNST BDSI
April 25, 2022 | americanbankingnews.com
BioDelivery Sciences International (NASDAQ:BDSI) Coverage Initiated by Analysts at StockNews.com
April 5, 2022 | benzinga.com
Why Collegium Pharmaceutical's Shares Are Trading Higher Today
February 24, 2022 | finance.yahoo.com
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
February 24, 2022 | seekingalpha.com
BioDelivery Sciences launches migraine therapy in U.S.
February 24, 2022 | finance.yahoo.com
BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?
February 14, 2022 | apnews.com
BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to Shareholders
February 14, 2022 | apnews.com
BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to Shareholders
February 14, 2022 | finance.yahoo.com
BioDelivery's stock rockets toward a 2-year high after buyout deal with Collegium at a 54% premium
February 7, 2022 | finance.yahoo.com
Why the Earnings Surprise Streak Could Continue for BioDelivery (BDSI)
February 6, 2022 | nasdaq.com
BioDelivery Sciences International (NASDAQ:BDSI) Could Easily Take On More Debt
January 31, 2022 | finance.yahoo.com
Should Value Investors Pick BioDelivery (BDSI) Stock Now?
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:BDSI
Previous Symbol
CUSIP
09060J10
CIK
1103021
Web
www.bdsi.com
Phone
(919) 582-9050
Fax
919-582-9051
Employees
200
Year Founded
1997

Sales & Book Value

Annual Sales
$166.70 million
Price / Sales
3.46
Cash Flow
$0.36 per share
Price / Cash Flow
15.42
Book Value
$1.90 per share
Price / Book
2.94

Profitability

EPS (Most Recent Fiscal Year)
$0.829990
Net Income
$84.86 million
Net Margins
50.90%
Pretax Margin
17.77%
Return on Equity
21.25%
Return on Assets
10.56%

Debt

Debt-to-Equity Ratio
0.29
Current Ratio
2.45
Quick Ratio
2.17

Price-To-Earnings

Trailing P/E Ratio
6.74
Forward P/E Ratio
14.71
P/E Growth
N/A

Miscellaneous

Outstanding Shares
103,229,000
Free Float
92,927,000
Market Cap
$577.05 million
Optionable
Optionable

Company Calendar

Last Earnings
3/09/2022
Today
5/20/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank™

Overall MarketRank™

2.36 out of 5 stars

Medical Sector

223rd out of 1,420 stocks

Pharmaceutical Preparations Industry

84th out of 679 stocks

Analyst Opinion: 2.1Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -













BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

Is BioDelivery Sciences International a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BioDelivery Sciences International stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BDSI, but not buy additional shares or sell existing shares.
View analyst ratings for BioDelivery Sciences International or view top-rated stocks.

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) released its quarterly earnings data on Wednesday, March, 9th. The specialty pharmaceutical company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.02. The specialty pharmaceutical company earned $43.15 million during the quarter, compared to analyst estimates of $41.84 million. BioDelivery Sciences International had a net margin of 50.90% and a trailing twelve-month return on equity of 21.25%.
View BioDelivery Sciences International's earnings history.

What price target have analysts set for BDSI?

6 analysts have issued 1 year price objectives for BioDelivery Sciences International's shares. Their forecasts range from $4.50 to $10.00. On average, they anticipate BioDelivery Sciences International's stock price to reach $6.43 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts' price targets for BioDelivery Sciences International or view top-rated stocks among Wall Street analysts.

Who are BioDelivery Sciences International's key executives?
BioDelivery Sciences International's management team includes the following people:
  • Mr. Jeffrey Allen Bailey, CEO & Director (Age 59, Pay $599.96k)
  • Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 57, Pay $629.46k)
  • Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 53, Pay $586.68k) (LinkedIn Profile)
  • Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 61, Pay $570.06k)
  • Mr. John Golubieski, CFO & Chief Accounting Officer (Age 57)
  • Mr. Joseph M. Lockhart, Sr. VP of Operations
  • Mr. Kevin Ostrander, Sr. VP of Bus. Devel.
  • Dr. Bill McCarberg, Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
  • Dr. Arthur G. Lipman PharmD, Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
  • Dr. Jeff Katz, Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), JD.com (JD), Baidu (BIDU), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by a number of institutional and retail investors. Top institutional investors include Group One Trading L.P. (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Company insiders that own BioDelivery Sciences International stock include James Vollins, Jeffrey Allen Bailey, Kevin Kotler, Mark A Sirgo, Mary Theresa Coelho and W Mark Watson.
View institutional ownership trends for BioDelivery Sciences International.

Which institutional investors are selling BioDelivery Sciences International stock?

BDSI stock was sold by a variety of institutional investors in the last quarter, including Simplex Trading LLC, and Group One Trading L.P..
View insider buying and selling activity for BioDelivery Sciences International or view top insider-selling stocks.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $5.59.

How much money does BioDelivery Sciences International make?

BioDelivery Sciences International has a market capitalization of $577.05 million and generates $166.70 million in revenue each year. The specialty pharmaceutical company earns $84.86 million in net income (profit) each year or $0.829990 on an earnings per share basis.

How many employees does BioDelivery Sciences International have?

BioDelivery Sciences International employs 200 workers across the globe.

When was BioDelivery Sciences International founded?

BioDelivery Sciences International was founded in 1997.

What is BioDelivery Sciences International's official website?

The official website for BioDelivery Sciences International is www.bdsi.com.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at (919) 582-9050, via email at [email protected], or via fax at 919-582-9051.

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.